This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

8 Stocks Rising on Monster Volume

Stocks in this article: THRX AFFY LGND KALU Z RDEN LFUS ANIK

Theravance

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Theravance (THRX) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. This stock is trading up 17.9% at $23 in recent trading.

Today's Volume: 849,000

Average Volume: 689,326

Volume % Change: 222%

Shares of THRX are soaring today on news that partner GlaxoSmithKline (GSK) plans to increase its stake in the biotech group from 18.3% to 26.8%.

From a technical perspective, THRX is ripping higher today on above average volume. This move is quickly pushing THRX within range of triggering a big breakout trade. That trade will hit once THRX takes out some past overhead resistance levels at $24.27 to $25.40 with high-volume.

Traders should look for long-biased trades if THRX can manage to move and close above those levels on volume that's near or well above 689,326 shares. If we get that action soon, watch for THRX to re-test its next significant overhead resistance levels at $27 to $28.95 in the near future.

Theravance is one of the top holdings of Seth Klarman's Baupost Group, which has a 14.2 million-share position in the stock as of the most recently reported quarter.

2 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,806.40 +28.25 0.16%
S&P 500 2,074.67 +13.44 0.65%
NASDAQ 4,777.6440 +29.2480 0.62%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs